SIMULTANEOUS ESTIMATION OF REMOGLIFLOZIN ETABONATE AND TENELIGLIPTIN HYDROBROMIDE HYDRATE IN TABLET DOSAGE FORM BY RP-HPLC METHOD

Abstract

A simple, precise, accurate method was developed for the simultaneous estimation of Remogliflozin etabonate and Teneligliptin Hydrobromide Hydrate in tablet dosage form by RP-HPLC method. The separation was achieved by Force scientific C₁₈ (250mm x 4.6mm, 5µm) column and Methanol: Phosphate buffer (pH 3) in the ratio of (70:30) as mobile phase, at a flow rate of 1 ml/min. Detection was carried out at 235 nm. Remogliflozin etabonate and Teneligliptin Hydrobromide Hydrate had respective retention times of 16.1 minutes and 3.4 minutes. The approach's linearity, accuracy, precision, and robustness have all been validated. Remogliflozin etabonate 12.5-75 g/ml and Teneligliptin Hydrobromide Hydrate 1.25-7.5 g/ml showed linearity with correlation coefficients of 0.9998 and 0.9984, respectively. For the simultaneous measurement of remogliflozin etabonate and teneligliptin hydrobromide hydrate in their tablet dosage form, the developed approach was proven to be accurate, exact, and quick.